Breast Cancer Res by Ma, Huiyan et al.
RESEARCH ARTICLE Open Access
Body mass index at age 18 years and recent
body mass index in relation to risk of breast
cancer overall and ER/PR/HER2-defined
subtypes in white women and
African-American women: a pooled analysis
Huiyan Ma1* , Giske Ursin2,3, Xinxin Xu1, Eunjung Lee4, Kayo Togawa1,5, Kathleen E. Malone6,
Polly A. Marchbanks7, Jill A. McDonald8, Michael S. Simon9, Suzanne G. Folger7, Yani Lu1, Jane Sullivan-Halley1,
Dennis M. Deapen4, Michael F. Press10 and Leslie Bernstein1
Abstract
Background: Although it has been well-documented that obesity is associated with decreased risk of premenopausal
breast cancer and increased risk of postmenopausal breast cancer, it is unclear whether these associations differ among
breast cancer subtypes defined by the tumor protein expression status of estrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor 2 (HER2).
Methods: We evaluated the associations of body mass index (BMI) at age 18 years and recent BMI in relation to
risk of breast cancer overall and ER/PR/HER2-defined subtypes, in 6320 women (3934 case-patient participants,
2386 control participants) aged 35–64 years, who participated in one of three population-based case-control studies.
We estimated multivariable-adjusted odd ratios (ORs) and corresponding 95% confidence intervals (CIs) using
polychotomous unconditional logistic regression methods for case-control comparisons in premenopausal women
and postmenopausal women.
Results: BMI at age 18 years was inversely associated with risk of breast cancer, particularly among premenopausal
women (≥ 25 vs. < 20 kg/m2, OR = 0.72, 95% CI = 0.53–0.96; per 5 kg/m2 increase, OR = 0.83, 95% CI = 0.73–0.95). This
inverse association did not differ across ER/PR/HER2-defined subtypes or by race (white women, African-American
women). Recent BMI was not associated with risk of premenopausal breast cancer after adjustment for BMI at age 18
years; nevertheless, the analysis for the joint effects of BMI at age 18 years and recent BMI showed that premenopausal
women in the highest categories of the two BMI measures (≥ 25 kg/m2 at age 18 years and ≥ 30 kg/m2 for recent BMI)
had 46% lower risk of breast cancer than premenopausal women in the lowest categories of the two BMI measures (<
20 kg/m2 at age 18 years and < 25 kg/m2 for recent BMI; OR = 0.54, 95% CI = 0.38–0.78). Neither measure of BMI was
statistically significantly associated with risk of postmenopausal breast cancer.
Conclusion: Our findings indicate that high BMI near the end of adolescence decreases risk of all ER/PR/HER2-defined
subtypes of premenopausal breast cancer and also suggest that this benefit could be maximized among premenopausal
women who consistently have high BMI during their premenopausal years.
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Background
The prevalence of obesity (defined as a body mass index
(BMI) of 30 kg/m2 or greater) has dramatically increased
since the 1980s [1]. Convincing epidemiologic evidence
indicates that obesity is associated with decreased risk of
premenopausal breast cancer and increased risk of post-
menopausal breast cancer [2]. However, it is unclear
whether obesity impacts the tumorigenesis of all breast
cancers or only certain breast cancer subtypes as defined
by the tumor protein expression status of the estrogen
receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2).
Munsell et al. [3] conducted a meta-analysis of 57 epi-
demiologic studies published between 1980 and 2012 on
the associations between obesity and risk of breast can-
cer subtypes defined by ER and PR. They reported that
obese women had 22% lower risk of premenopausal ER-
positive (ER+)/PR+ breast cancer than premenopausal
women with BMI lower than 25 kg/m2 (summary risk ra-
tio = 0.78, 95% confidence interval (95% CI) = 0.67–0.92)
and 39% higher risk of postmenopausal ER+/PR+ breast
cancer than postmenopausal women with BMI lower than
25 kg/m2 (summary risk ratio = 1.39, 95% CI =1.14–1.70).
In the same study, obesity was not associated with the risk
of ER-negative (ER–)/PR– breast cancer in either premen-
opausal women or postmenopausal women.
Pierobon et al. [4] used meta-analysis to summarize
the findings of 11 epidemiologic studies published be-
tween May 2008 and February 2012 that assessed the as-
sociation between obesity and risk of triple negative
breast cancer (TNBC (ER–/PR–/HER2–)). They con-
cluded that, in a case-case comparison of TNBC or
basal-like subtype with receptor-positive subtype, obese
premenopausal women had 43% greater risk of TNBC
than non-obese premenopausal women, but that obesity
was not associated with risk of TNBC in postmeno-
pausal women (premenopausal women, summary odds
ratio (OR) = 1.43, 95% CI = 1.23–1.65; postmenopausal
women, summary OR = 0.99, 95% CI = 0.79–1.24).
Bandera et al. [5] present results from the African
American Breast Cancer Epidemiology and Risk
(AMBER) Consortium showing that, among premeno-
pausal women, BMI at age 18 years was inversely associ-
ated with risk of ER+ breast cancer but not with risk of
ER– breast cancer or TNBC (BMI ≥30 vs. BMI = 20–
24.9 kg/m2, ER+ OR = 0.65, 95% CI = 0.42–1.01; ER– OR
= 1.00, 95% CI = 0.63–1.58; TNBC OR= 1.08, 95% CI =
0.59–1.98). However, among postmenopausal women,
BMI at age 18 years was associated with decreased risk of
all subtypes of breast cancer (BMI ≥30 vs. BMI = 20–
24.9 kg/m2, ER+ OR = 0.62, 95% CI = 0.38–1.01; ER– OR
= 0.78, 95% CI = 0.44–1.41; TNBC OR= 0.68, 95% CI =
0.29–1.56). They also found that high BMI immediately
before diagnosis (cases) or an index date (controls) was
not associated with the risk of ER–, ER+, or TNBC in
premenopausal women, but was associated with 31%
increased risk of ER+ breast cancer (BMI ≥35 vs. BMI
< 25 kg/m2, OR =1.31, 95% CI = 1.02–1.67) and 40%
decreased risk of TNBC in postmenopausal women
(BMI ≥ 35 vs. BMI < 25 kg/m2, OR =0.60, 95% CI =
0.39–0.93).
Given the lack of consistency in results for analysis of
BMI in relation to tumor marker subtypes of breast can-
cer, especially TNBC, additional research is needed to
clarify whether obesity impacts all subtypes of breast
cancer or only certain receptor-defined subtypes. More-
over, it remains unclear whether associations differ
among racial/ethnic groups.
Here we present results from a pooled analysis of data
from three population-based breast cancer case-control
studies conducted among white women and African-
American women [6–8]; we examine the associations
between BMI at age 18 years and BMI 5 years before
case patients’ breast cancer diagnosis or control partici-
pants’ index date (herein referred to as “recent BMI”) in
relation to risk of breast cancer overall and risk of breast
cancer subtypes defined by ER, PR, and HER2.
Methods
Study population and data collection
Eligible participants for this analysis were women who
participated in one of the three population-based case-
control studies – the Women’s Contraceptive and
Reproductive Experiences (CARE) Study [6], the
Women’s Breast Carcinoma in situ (BCIS) Study [7], or
the Women’s Learning the Influence of Family and
Environment (LIFE) Study [8].
The Women’s CARE Study was a population-based,
multi-site, case-control study designed to examine risk
factors for invasive breast cancer among US-born white
women and African-American women [9]. The age dis-
tribution and participant response rates by study site,
case-control status, and race have previously been pub-
lished [9]. The Women’s CARE Study selected a strati-
fied (by age group) random sample of women aged 35 to
64 years who were newly diagnosed with their first pri-
mary, histologically confirmed invasive breast cancer
(International Classification of Diseases for Oncology
(ICD-O) codes C50.0–C50.9) between July 1994 and
April 1998. African-American women were oversampled
to maximize their numbers in the study, and white
women were sampled to provide approximately equal
numbers of women in each 5-year age category (from 35
to 64 years). Control participants were women with no
history of invasive or in situ breast cancer who were
identified by random digit dialing between August 1994
and December 1998; control participants were frequency
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matched to the expected age and race distribution of
cases within each geographic region of residence [6].
The Women’s CARE Study participants included in this
pooled analysis are from Los Angeles and Detroit, the two
study sites where tumor tissue samples were collected.
Details of tissue collection for case-patient participants at
the two sites have been described previously [6]. The
Women’s CARE Study recruited 1921 case-patient parti-
cipants (1072 white and 849 African-American women)
and 2034 control participants (1161 white and 873
African-American women) from Los Angeles and Detroit.
Of 1921 case-patient participants, 1206 had ER/PR/HER2
status assessed in a centralized pathology laboratory at the
University of Southern California (USC).
The Women’s BCIS Study investigated risk factors for
BCIS among US-born white women and African-
American women who resided in Los Angeles County
[7]. Case-patient participants were US-born and English
speaking white women and African-American women
ages 35–64 years, who were newly diagnosed with a first
primary BCIS (ICD-O codes C50.0–C50.9) between
March 1995 and April 1998 (n = 567; 475 white and 92
African-American women). The Women’s BCIS Study
was conducted at the same time as the Women’s CARE
Study and used the same methodology. Specifically, the
two studies used the same questionnaire, same study in-
terviewers, and same central laboratory and classification
scheme for ER, PR, and HER2 status (see below). In
addition, Los Angeles control participants from the
Women’s CARE Study also served as controls for the
BCIS Study. For this pooling project, we excluded 37
Women’s BCIS Study case-patient participants with
lobular carcinoma in situ (LCIS, ICD-O morphology
code 8520) because LCIS is generally not included in
clinical definitions of in situ breast cancer [10]; thus 530
case-patient participants (444 white and 86 African-
American women) were considered eligible for this pool-
ing project. Among these case patients, 343 had ER/PR/
HER2 status assessed by the centralized pathology
laboratory at USC.
The Women’s LIFE Study investigated genetic and
epidemiologic risk factors for invasive breast cancer in
US-born white women and African-American women
who resided in Los Angeles County [8, 11]. Case-patient
participants were women aged 20–49 years who were di-
agnosed with a first primary invasive breast cancer
(ICD-O codes: C50.0–C50.9) between February 1998
and May 2003 (n = 1794; 1585 white and 209 African-
American women). Control participants were women
ages 20–49 years who had no history of invasive or in
situ breast cancer. Control participants were individually
matched by race (white and African-American), age
(within 5 years and ages 20–49 years), and neighborhood
of residence, to the subset of case-patient participants
who were diagnosed between 1 July 2000 and 31 May
2003 (n = 444; 409 white and 35 African-American
women). The Women’s LIFE Study used an expanded
version of the Women’s CARE Study questionnaire and
abstracted tumor marker status from pathology reports
collected by the Los Angeles Cancer County Surveillance
Program (LACSP) with ER available for 1569 (87.4%) pa-
tients, PR available for 1439 (80.2%) patients, and HER2
available for 1206 (67.3%) patients.
For all three studies, detailed information about body
size measures and covariates prior to the reference date
was collected by trained staff in standardized in-person
interviews. The reference date for a case-patient partici-
pant was the date of her breast cancer diagnosis; the ref-
erence date for a control participant was the date she
was identified by random digit dialing in the Women’s
CARE Study, or the date of initial contact in the
Women’s LIFE Study.
Anthropometric variables involved in this analysis in-
clude: tallest height without shoes, usual weight (if preg-
nant, the pre-pregnancy weight was used) at age
18 years and 5 years before reference age (termed “re-
cent weight”). BMI at each time point was calculated as
the corresponding body weight in kilograms divided by
height in meters squared (kg/m2). Based on the World
Health Organization’s guideline [12], three categories of
“recent BMI” were created: underweight/normal weight,
<25.0 kg/m2; overweight, 25.0–29.9 kg/m2; and obese,
≥30.0 kg/m2. Because only 1.6% of women at age 18 years
had a BMI of 30 kg/m2 or higher and 47.8% had a BMI
that was lower than 20.0 kg/m2, we used previously pub-
lished categories for BMI at age 18 years (< 20.0, 20.0–
24.9, ≥25.0 kg/m2) [13]. None of our three source studies
has published on the association between BMI and ER/
PR/HER2-defined breast cancer subtypes, whereas two
of our three source studies previously published papers
describing the association between BMI and ER/PR-de-
fined subtypes [8, 14].
After pooling the data from the three source studies,
6723 women (4245 case-patient participants and 2478
control participants) were potentially eligible for this
analysis. We excluded 160 case-patient participants and
64 control participants for whom information was miss-
ing on the following factors: age at menarche (4 cases, 1
control), parity (8 cases, 6 controls), duration of oral
contraceptive use (23 cases, 5 controls), education (15
cases, 1 control), BMI at age 18 years (15 cases, 4 con-
trols), recent BMI (18 cases, 12 controls), recreational
physical activity (6 cases, 3 controls), smoking status (8
cases), alcohol intake (10 cases, 2 controls), and meno-
pausal status (53 cases, 30 controls). We were unable to
determine menopausal status for 53 case patients and 30
control participants who had a hysterectomy with at
least a portion of one ovary remaining (9 cases, 12
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controls), began menopausal hormone therapy (MHT)
use within 12 months of their last menstrual period (20
cases, 10 controls), or did not answer the questions re-
garding menopausal status and MHT use (24 cases, 8
controls). We also excluded 179 participants (151 cases,
28 controls) in the Women’s LIFE Study who were
younger than 35 years at diagnosis or reference date,
since the age range for the Women’s CARE and BCIS
studies was 35 to 64 years.
After these exclusions, 3934 case-patient participants
(1873 from the Women’s CARE Study, 517 from the
Women’s BCIS Study, and 1544 from the Women’s LIFE
Study) and 2386 control participants (1982 from the
Women’s CARE Study, of whom 1226 Los Angeles con-
trol participants were also used for the Women’s BCIS
Study, and 404 from the Women’s LIFE Study) remained
and were included in the pooled analysis.
Assessment of biomarkers
As noted above, we determined ER/PR/HER2 receptor
status of the breast cancers in case-patient participants
in the Women’s CARE Study and Women’s BCIS Study
in a centralized clinical laboratory improvement act
(CLIA)-approved, College of American Pathologists
(CAP)-certified pathology laboratory at USC using im-
munohistochemistry (IHC) methods [15, 16]. For ER
and PR, at least 100 tumor cells were examined for each
specimen; a specimen was considered as positive for the
receptor if at least 1% of the tumor cell nuclei were im-
munostained [17]. HER2 expression was determined by
IHC using the 10H8 monoclonal antibody [18, 19]. No
(0) or weak (1+) membrane immunostaining was consid-
ered HER2–. Moderate (2+) or strong membrane immu-
nostaining (3+) was considered HER2+, based on
previous validation results from the same pathology la-
boratory [18]. ER/PR/HER2 status for case-patient par-
ticipants in the Women’s LIFE Study was abstracted
from pathology reports collected through the LACSP
[20], a member of the population-based California
Cancer Registry and also sponsored by the National
Cancer Institute’s Surveillance, Epidemiology and End
Results (SEER) program.
Of 3934 case-patient participants, 2861 (72.7%) had ER
status, 2740 (69.7%) had PR status, and 2560 (65.1%) had
HER2 status. In our analysis, we classified case-patient
participants into four subgroups: TNBC (ER–/PR–/
HER2–, n = 515), luminal-like breast cancer (ER+ and/or
PR+, n = 2056), HER2-enriched breast cancer (ER–/PR–/
HER2+, n = 212), and an unclassified group (n = 1151)
[21]. To determine whether the impact of BMI varied
across subtypes of luminal-like breast cancer, we further
classified 1797 luminal-like tumors with information avai-
lable for all three markers into luminal A-like (ER+/PR
+/HER2–, n = 1175), luminal B-like-HER2– (ER+ or PR+
plus HER2–, n = 283), or luminal B-like-HER2+ (ER+
and/or PR+ plus HER2+, n = 339), based on the 13th St.
Gallen International Breast Cancer Conference (2013) Ex-
pert Panel recommendation [22]. It is noteworthy that the
St. Gallen Panel recommendation requires information on
Ki-67 and percentage of PR in PR+ tumors; however, we
lacked data on Ki-67 in each of the studies and did not
have quantitative data for PR in the Women’s LIFE Study.
Statistical analyses
We assessed whether BMI at age 18 years and recent
BMI were associated with breast cancer overall and ER/
PR/HER2-defined subtypes, estimating ORs and corre-
sponding 95% CIs from multivariable polychotomous un-
conditional logistic regression models [23]. These models
were fit separately for premenopausal women and post-
menopausal women. For each of the BMI measures, we
first estimated the OR and 95% CI associated with each
level of a categorical variable. We then estimated the OR
and 95% CI associated with each 5 kg/m2 increase in the
BMI measure, and assessed whether this 5 kg/m2 increase
in BMI differed from the null using the Wald chi-square
test. Finally after conducting these analyses for each sub-
type, we tested for homogeneity of the 5 kg/m2 slope co-
efficients across ER/PR/HER2-defined subtypes.
In our analysis, women were considered premeno-
pausal if they were still menstruating and had not taken
any MHT during the 12 months before the reference
date. We classified women as postmenopausal if they
had experienced a natural menopause (had a final men-
strual period > 12 months before the reference date and
had not used MHT before or during the 12-month inter-
val after the last menstrual period), had a surgical meno-
pause (had undergone bilateral oophorectomy with the
second ovary removed at least 12 months before the ref-
erence date), or had an induced menopause (periods
stopped because of chemotherapy or radiation therapy
at least 12 months before the reference date). Consider-
ing the possibility that associations with recent BMI
among postmenopausal women might be modified by
MHT use [24], we also assessed these associations strati-
fied by MHT use.
For premenopausal women, in which we observed an
inverse association between BMI at age 18 years and
breast cancer risk, we further conducted race-stratified
analyses (white women, African-American women) for
breast cancer overall and for two major subtypes
(luminal-like and TNBC). Finally, we assessed the joint
effects of BMI at age 18 years and recent BMI (using a
variable that combined these two variables) in premeno-
pausal women for breast cancer overall and for the
luminal-like subtype (the most common subtype). We
did not do race-stratified analyses for the HER2-
enriched subtype nor did we assess the joint effects of
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BMI at age 18 years and recent BMI for either the
HER2-enriched subtype or TNBC, due to limited sample
size. For postmenopausal women, we did not conduct
race-stratified analyses or assess the joint effects of the
two BMI measures due to the limited numbers of post-
menopausal women in some subgroups.
Our models assessing effects of BMI at age 18 years or
recent BMI included both BMI variables (i.e., each was
mutually adjusted for the other). All models also in-
cluded the following factors, selected a priori, as poten-
tial confounders in all multivariable models: source
study (the Women’s CARE Study or the Women’s BCIS
Study, the Women’s LIFE Study), study site (Los
Angeles, Detroit), race (white, African-American), edu-
cation as a proxy for socioeconomic status (high school
or lower level of education, technical school or some
college, college graduate), reference age (premenopausal
women < 40, 40–44, ≥ 45 years; postmenopausal women
< 50, 50–54, 55–59, 60–64 years), family history of
breast cancer (first-degree (mother, sister, or daughter),
no first-degree family history), age at menarche (≤ 12,
13, ≥ 14 years), number of completed (greater than 26-
week gestation) pregnancies (never pregnant, 1, 2, ≥ 3,
only non-completed pregnancy), lifetime recreational
physical activity (inactive, ≤ 2.2, 2.3–6.6, 6.7–15.1, ≥15.2
annual metabolic equivalents of energy expenditure
(MET) hour/week), alcohol intake (never, former,
current), cigarette smoking status (never, former,
current), and oral contraceptive use (never, < 1, 1–4, 5–
9, ≥ 10 years). In the analyses of postmenopausal women
overall, we additionally adjusted for MHT use (never
use, ever use).
We repeated our analyses limiting data to the two
source studies with ER/PR/HER2 status obtained by the
centralized laboratory to assess whether using ER/PR/
HER2 status from multiple laboratories in the LIFE
Study (obtained from the LACSP) would influence our
results. In another analysis, we restricted case-patient
participant data to those obtained from women diag-
nosed with invasive breast cancer.
In reporting the results of statistical tests determining
whether the 5 kg/m2 increase in BMI (slope coefficient)
differed from the null (test for trend) or whether slope
coefficients differed across ER/PR/HER2-defined subtypes
(test for homogeneity of trends) we considered a two-
sided P value less than 0.05 as statistically significant. All
analyses were performed using the SAS statistical package
(Version 9.4, SAS Institute, Cary, NC, USA).
Results
Characteristics of cases and controls
Overall, mean age at reference date was 47.3 and 47.9 years
for case-patient participants and control participants, re-
spectively (Table 1). By menopausal status, 61.7% of case-
patient participants were premenopausal and 38.3% were
postmenopausal; among control participants, 52.7% were
premenopausal and 47.3% were postmenopausal. By race,
72.4% of case-patient participants were white women and
27.6% were African-American women; among control
participants, 63.0% were white women and 37.0% were
African-American women. Overall, the percentage of par-
ticipants who were overweight or obese during early
adulthood was 6.9% and 9.0% for case-patient and control
participants, respectively; the percentage of recent obesity
was 17.1% and 19.4% for case-patient and control partici-
pants, respectively.
Risk of breast cancer overall and ER/PR/HER2-defined
subtypes associated with BMI at age 18 years or recent BMI
In premenopausal women, BMI at age 18 years was in-
versely associated with risk of breast cancer overall (≥ 25
vs. < 20 kg/m2, OR = 0.72, 95% CI = 0.53–0.96; per 5 kg/m2
increase, OR = 0.83, 95% CI = 0.73–0.95, Table 2). The in-
verse association per 5 kg/m2 increase in BMI at age
18 years did not differ by subtype (P for homogeneity of
slope coefficients per 5 kg/m2 increase = 0.15).
Recent BMI was not associated with risk of premeno-
pausal breast cancer overall. However, our analyses of ER/
PR/HER2-defined subtypes in premenopausal women
showed some evidence that recent obesity affected ER/
PR/HER2-defined subtypes differently, with no association
for luminal-like subtype and potentially increased risks of
TNBC and HER2-enriched subtypes (per 5 kg/m2 in-
crease, luminal-like OR = 0.97, 95% CI = 0.88–1.07; TNBC
OR= 1.14, 95% CI = 1.00–1.31; HER2-enriched OR = 1.19,
95% CI = 0.98–1.45; P for homogeneity of slope coeffi-
cients per 5 kg/m2 increase = 0.02).
In postmenopausal women, BMI at age 18 years was
not associated with risk of breast cancer overall
although the OR was reduced more than 20% when
comparing overweight and obese women to thin
women (≥ 25 vs. < 20 kg/m2, OR = 0.79, 95% CI = 0.56–
1.11; per 5 kg/m2 increase, OR = 0.98, 95% CI = 0.85–
1.14); no differences in risk across ER/PR/HER2-defined
subtypes was observed (P value for homogeneity of regres-
sion coefficients = 0.20). Furthermore, recent BMI was not
associated with risk of breast cancer overall, TNBC,
luminal-like subtype, or HER2-enriched subtype in post-
menopausal women. Among postmenopausal women
who had never used MHT, risk of the luminal-like subtype
was 1.5-fold greater among women who were obese than
among women who were normal weight or thin (≥ 30 vs.
< 25 kg/m2, OR = 1.55, 95% CI = 1.00–2.41).
Analyses sub-classifying luminal-like breast cancer into
luminal A-like, luminal B-like-HER2–, and luminal B-like-
HER2+, did not provide any evidence that the associations
of BMI at age 18 years or recent BMI in either
Ma et al. Breast Cancer Research  (2018) 20:5 Page 5 of 14
premenopausal women or postmenopausal women varied
across these breast cancer subtypes (results not shown).
Race-stratified risk of premenopausal breast cancer
overall, TNBC, and luminal-like subtype associated with
BMI at age 18 years or recent BMI
A modest inverse association was observed between
BMI at age 18 years and premenopausal breast cancer
overall in both white women and African-American
women (per 5 kg/m2 increase, white women, OR = 0.86,
95% CI = 0.73–1.02; African-American women, OR =
0.79, 95% CI = 0.62–1.00, Table 3). The inverse associa-
tions were also observed with two major ER/PR/HER2-
defined subtypes (luminal-like and TNBC) in both
premenopausal white women (per 5 kg/m2 increase, OR
for TNBC = 0.61, 95% CI = 0.44–0.86; OR for luminal-
like subtype = 0.87, 95% CI = 0.71–1.06) and premeno-
pausal African-American women (per 5 kg/m2 in-
crease, OR for TNBC = 0.78, 95% CI = 0.54–1.15; OR
for luminal-like subtype = 0.74, 95% CI = 0.54–1.03).
In premenopausal white women, recent obesity was
associated with a reduced risk for breast cancer overall
and for luminal-like subtype, but was not associated with
TNBC (≥ 30 vs. < 25 kg/m2, overall OR = 0.72, 95% CI =
0.53–0.97; luminal-like OR = 0.71, 95% CI = 0.50–1.01;
TNBC OR = 1.00, 95% CI = 0.57–1.75). Recent BMI was
not associated with risk of breast cancer overall or the
two subtypes in premenopausal African-American
women (≥ 30 vs. < 25 kg/m2, overall OR = 1.02, 95% CI
Table 1 Characteristics of breast cancer case-patient participants and control participants by study
Overall Women’s CARE Study Women’s
BCIS Study
Women’s LIFE Study
Number of
cases (%)
Number of
controls (%)
Number of
cases (%)
Number of controlsa
(%)
Number of
cases (%)
Number of
cases (%) Number of controls (%)
Number of participants 3934 2386 1873 1982 517 1544 404
Subtype of breast cancer
Unclassified 1151 ─ 691 ─ 182 278 ─
Classified 2783 ─ 1182 ─ 335 1266 ─
Triple negative
(ER–/PR–/HER2–)
515 (18.5) ─ 329 (27.8) ─ 21 (6.3) 165 (13.0) ─
Luminal-like (ER+
and/or PR+)
2056 (73.9) 758 (64.1) 277 (82.7) 1021 (80.7)
HER2-enriched
(ER–/PR–/HER2+)
212 (7.6) ─ 95 (8.0) ─ 37 (11.0) 80 (6.3) ─
Mean age at reference
date, years (SD)
47.3 (7.4) 47.9 (8.1) 48.9 (8.5) 48.8 (8.4) 51.5 (7.3) 44.0 (3.9) 43.5 (3.8)
Menopausal status
Premenopausal 2427 (61.7) 1257 (52.7) 929 (49.6) 927 (46.8) 203 (39.3) 1295 (83.9) 330 (81.7)
Postmenopausal 1507 (38.3) 1129 (47.3) 944 (50.4) 1055 (53.2) 314 (60.7) 249 (16.1) 74 (18.3)
Never used MHT 650 (43.1) 466 (41.3) 409 (43.3) 430 (40.8) 107 (34.1) 134 (53.8) 36 (48.7)
Ever used MHT 857 (56.9) 663 (58.7) 535 (56.7) 625 (59.2) 207 (65.9) 115 (46.2) 38 (51.3)
Race
White 2849 (72.4) 1503 (63.0) 1056 (56.4) 1134 (57.2) 435 (84.1) 1358 (88.0) 369 (91.3)
African-American 1085 (27.6) 883 (37.0) 817 (43.6) 848 (42.8) 82 (15.9) 186 (12.0) 35 (8.7)
BMI at age 18 years, kg/m2
< 20.0 1921 (48.8) 1110 (46.5) 882 (47.1) 906 (45.7) 286 (55.3) 753 (48.8) 204 (50.5)
20.0–24.9 1740 (44.2) 1061 (44.5) 848 (45.3) 893 (45.1) 207 (40.0) 685 (44.4) 168 (41.6)
≥ 25.0 273 (6.9) 215 (9.0) 143 (7.6) 183 (9.2) 24 (4.6) 106 (6.9) 32 (7.9)
Recent BMI, kg/m2
< 25.0 2292 (58.3) 1271 (53.3) 985 (52.6) 1003 (50.6) 345 (66.7) 962 (62.3) 268 (66.3)
25.0–29.9 968 (24.6) 652 (27.3) 511 (27.3) 570 (28.8) 115 (22.2) 342 (22.2) 82 (20.3)
≥ 30.0 674 (17.1) 463 (19.4) 377 (20.1) 409 (20.6) 57 (11.0) 240 (15.5) 54 (13.4)
Abbreviations: ER estrogen receptor, PR progesterone receptor, HER2, human epidermal growth factor receptor-2, BMI body mass index, CARE Contraceptive and
Reproductive Experiences, BCIS Breast Carcinoma in situ, LIFE Learning the Influence of Family and Environment, MHT menopausal hormone therapy
aIncluding those who also served as controls for the Women’s BCIS Study
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Table 2 Adjusteda odds ratio (OR) and 95% confidence interval (CI) for breast cancer overall and ER/PR/HER2-defined subtypes
associated with BMI in premenopausal women and postmenopausal women
Controls All cases Triple negative
(ER–/PR–/HER2–)
Luminal-like
(ER+ and/or PR+)
HER2-enriched
(ER–/PR–/HER2+)
Unclassified
Number Number OR (95% CI) Number OR (95% CI) Number OR (95% CI) Number OR (95% CI) Number OR (95% CI)
Premenopausal
BMI at age 18 years, kg/m2
< 20.0 588 1187 Referent 160 Referent 656 Referent 71 Referent 300 Referent
20.0–
24.9
543 1067 0.99 (0.84–
1.16)
144 0.91 (0.69–
1.20)
577 0.97 (0.81–
1.17)
55 0.82 (0.55–
1.22)
291 1.09 (0.88–
1.35)
≥ 25.0 126 173 0.72 (0.53–
0.96)
25 0.62 (0.36–
1.04)
83 0.63 (0.44–
0.91)
6 0.36 (0.14–
0.92)
59 1.00 (0.68–
1.46)
Per 5 kg/m2 increase 0.83 (0.73–
0.95)
0.68 (0.53–
0.87)
0.80 (0.68–
0.95)
0.59 (0.40–
0.86)
1.00 (0.84–
1.19)
P value 0.007 0.002 0.008 0.006 0.98
P value for homogeneity of slope coefficients across three subtypes = 0.15
Recent BMI, kg/m2
< 25.0 758 1545 Referent 194 Referent 868 Referent 80 Referent 403 Referent
25.0–
29.9
299 533 0.90 (0.74–
1.08)
80 1.07 (0.78–
1.47)
269 0.82 (0.65–
1.02)
29 0.99 (0.61–
1.60)
155 0.92 (0.71–
1.17)
≥ 30.0 200 349 0.85 (0.67–
1.08)
55 1.12 (0.75–
1.67)
179 0.80 (0.60–
1.06)
23 1.34 (0.75–
2.38)
92 0.75 (0.54–
1.03)
Per 5 kg/m2 increase 1.00 (0.92–
1.08)
1.14 (1.00–
1.31)
0.97 (0.88–
1.07)
1.19 (0.98–
1.45)
0.94 (0.84–
1.05)
P value 0.94 0.06 0.58 0.07 0.26
P value for homogeneity of slope coefficients across three subtypes = 0.02
Postmenopausalb
BMI at age 18 years, kg/m2
< 20.0 522 734 Referent 89 Referent 358 Referent 40 Referent 247 Referent
20.0–
24.9
518 673 0.92 (0.78–
1.10)
83 0.97 (0.69–
1.39)
326 0.94 (0.76–
1.17)
35 0.88 (0.53–
1.44)
229 0.89 (0.70–
1.12)
≥ 25.0 89 100 0.79 (0.56–
1.11)
14 1.01 (0.52–
1.98)
56 0.99 (0.65–
1.50)
5 0.76 (0.27–
2.14)
25 0.51 (0.31–
0.85)
Per 5 kg/m2 increase 0.98 (0.85–
1.14)
0.98 (0.73–
1.32)
1.12 (0.94–
1.35)
0.76 (0.48–
1.20)
0.86 (0.70–
1.05)
P value 0.81 0.89 0.21 0.23 0.14
P value for homogeneity of slope coefficients across three subtypes = 0.20
Recent BMI, kg/m2
< 25.0 513 747 Referent 83 Referent 390 Referent 36 Referent 238 Referent
25.0–
29.9
353 435 0.95 (0.78–
1.16)
64 1.11 (0.76–
1.63)
193 0.88 (0.69–
1.12)
28 1.23 (0.71–
2.12)
150 0.93 (0.71–
1.21)
≥ 30.0 263 325 1.09 (0.86–
1.39)
39 0.95 (0.59–
1.55)
157 1.19 (0.89–
1.60)
16 1.11 (0.55–
2.25)
113 1.03 (0.75–
1.41)
Per 5 kg/m2 increase 0.97 (0.90–
1.06)
0.97 (0.82–
1.15)
0.98 (0.89–
1.09)
1.06 (0.83–
1.34)
0.95 (0.85–
1.07)
P value 0.54 0.74 0.74 0.66 0.39
P value for homogeneity of slope coefficients across three subtypes = 0.83
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= 0.68–1.53; luminal-like OR = 0.94, 95% CI = 0.55–1.59;
TNBC OR = 1.09, 95% CI = 0.58–2.05).
Joint effect of BMI at age 18 years and recent BMI on risk
of premenopausal breast cancer overall and risk of
luminal-like breast cancer
Premenopausal women in the highest categories of
the two BMI measures (≥ 25 kg/m2 at age 18 years
and ≥ 30 kg/m2 for recent BMI) had 46% lower risk
of breast cancer overall (OR = 0.54 and 95% CI =
0.38–0.78, Table 4) and 54% lower risk of luminal-like
subtype (OR = 0.46 and 95% CI = 0.29–0.73) than pre-
menopausal women whose BMI was in the lowest
categories for both measures (< 20 kg/m2 for BMI at
age 18 years and < 25 kg/m2 for recent BMI).
Similar results were obtained when analyses were re-
stricted to the two source studies with ER/PR/HER2 sta-
tus determined in the centralized laboratory (for the
highest categories of the two BMI measures vs. the low-
est categories of both measures: overall OR = 0.52, 95%
CI = 0.33–0.81; luminal-like OR = 0.46, 95% CI = 0.25–
0.86). When the analyses were restricted to premeno-
pausal invasive breast cancer case-patient participants
(excluding the BCIS Study), results again remained simi-
lar (for the highest categories of the two BMI measures
BMI vs. the lowest categories of both measures: overall
OR = 0.58, 95% CI = 0.40–0.84; luminal-like OR = 0.53,
95% CI = 0.33–0.85).
Discussion
We pooled data from three population-based case-
control studies that included white women and African-
American women ages 35–64 years. The analyses of
premenopausal women showed that BMI at age 18 years
was inversely associated with breast cancer risk overall
and with risk of each ER/PR/HER2-defined subtype of
breast cancer. These inverse associations did not differ
by race. We found no strong evidence of any inverse as-
sociation between recent BMI and risk of premeno-
pausal breast cancer except when we analyzed the joint
Table 2 Adjusteda odds ratio (OR) and 95% confidence interval (CI) for breast cancer overall and ER/PR/HER2-defined subtypes
associated with BMI in premenopausal women and postmenopausal women (Continued)
Controls All cases Triple negative
(ER–/PR–/HER2–)
Luminal-like
(ER+ and/or PR+)
HER2-enriched
(ER–/PR–/HER2+)
Unclassified
Number Number OR (95% CI) Number OR (95% CI) Number OR (95% CI) Number OR (95% CI) Number OR (95% CI)
Postmenopausal/never used
MHT
Recent BMI, kg/m2
< 25.0 186 283 Referent 33 Referent 148 Referent 15 Referent 87 Referent
25.0–
29.9
150 181 0.94 (0.68–
1.29)
27 0.92 (0.50–
1.71)
74 0.82 (0.55–
1.21)
11 0.98 (0.41–
2.34)
69 1.06 (0.70–
1.61)
≥ 30.0 130 186 1.39 (0.98–
1.99)
20 0.96 (0.50–
2.00)
86 1.55 (1.00–
2.41)
9 1.20 (0.44–
3.30)
71 1.42 (0.90–
2.25)
Per 5 kg/m2 increase 1.07 (0.95–
1.21)
0.99 (0.77–
1.27)
1.07 (0.92–
1.25)
1.10 (0.77–
1.56)
1.10 (0.94–
1.28)
P value 0.27 0.94 0.36 0.60 0.26
P value for homogeneity of slope coefficients across three subtypes = 0.81
Postmenopausal/ever used MHT
Recent BMI, kg/m2
< 25.0 327 464 Referent 50 Referent 242 Referent 21 Referent 151 Referent
25.0–
29.9
203 254 0.93 (0.72–
1.21)
37 1.12 (0.67–
1.87)
119 0.89 (0.65–
1.22)
17 1.41 (0.68–
2.90)
81 0.86 (0.60–
1.22)
≥ 30.0 133 139 0.86 (0.62–
1.20)
19 0.87 (0.44–
1.69)
71 0.94 (0.63–
1.42)
7 0.91 (0.33–
2.50)
42 0.75 (0.47–
1.19)
Per 5 kg/m2 increase 0.90 (0.79–
1.01)
0.96 (0.75–
1.21)
0.92 (0.79–
1.06)
1.01 (0.71–
1.42)
0.82 (0.69–
0.98)
P value 0.07 0.71 0.24 0.98 0.03
P value for homogeneity of slope coefficients across three subtypes = 0.85
Abbreviations: ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor-2, BMI body mass index,
MHT menopausal hormone therapy
aORs obtained from multivariable polychotomous unconditional logistic regression models with mutual adjustment of BMI at age 18 years and recent BMI and
with adjustment for source study, study site, race, education, reference age, first-degree breast cancer family history, age at menarche, number of completed
pregnancies, lifetime recreational physical activity, alcohol intake, cigarette smoking status, and oral contraceptive use
bModel described (a) is additionally adjusted for MHT use
Ma et al. Breast Cancer Research  (2018) 20:5 Page 8 of 14
effects of BMI at age 18 years and recent BMI, which
showed marked inverse associations (range 46–54% de-
creases in risk) for breast cancer overall and for luminal-
like subtype comparing premenopausal women in the
highest categories of the two BMI measures (≥ 25 kg/
m2 at age 18 years and ≥ 30 kg/m2 for recent BMI)
with women in the lowest categories of the two BMI
measures (< 20 kg/m2 at age 18 years and < 25 kg/m2
for recent BMI). No compelling evidence was ob-
served among postmenopausal women for any associ-
ations between BMI at age 18 years or recent BMI
and breast cancer overall or ER/PR/HER2-defined
subtypes, except for a 1.5-fold increased risk of
luminal-like subtype associated with recent BMI
among postmenopausal women who had never used
MHT.
The Nurses’ Health Study [25], consisting of both
premenopausal women and postmenopausal women,
showed that BMI at age 18 years was inversely associ-
ated with risk of all subtypes defined according to ER/
PR/HER2, cytokeratin 5/6, and epidermal growth factor
receptor; however, results were not presented separately
Table 3 Adjusteda odds ratio (OR) and 95% confidence interval (CI) for breast cancer overall, triple negative breast cancer, and
luminal-like subtype associated with BMI in premenopausal white women and premenopausal African-American women
All cases Triple negative (ER–/PR–/HER2–) Luminal-like (ER+ and/or PR+)
Number OR (95% CI) Number OR (95% CI) Number OR (95% CI)
Premenopausal white women
BMI at age 18 years, kg/m2
< 20.0 946 Referent 108 Referent 553 Referent
20.0–24.9 793 1.01 (0.84–1.22) 91 0.92 (0.66–1.30) 470 1.03 (0.83–1.28)
≥ 25.0 121 0.76 (0.53–1.10) 12 0.53 (0.26–1.09) 64 0.73 (0.47–1.13)
Per 5 kg/m2 increase 0.86 (0.73–1.02) 0.61 (0.44–0.86) 0.87 (0.71–1.06)
P value 0.08 0.004 0.16
P value for homogeneity of slope coefficients between two subtypes = 0.04
Recent BMI, kg/m2
< 25.0 1274 Referent 136 Referent 754 Referent
25.0–29.9 373 0.87 (0.69–1.10) 51 1.30 (0.87–1.93) 205 0.78 (0.59–1.02)
≥ 30.0 213 0.72 (0.53–0.97) 24 1.00 (0.57–1.75) 128 0.71 (0.50–1.01)
Per 5 kg/m2 increase 0.95 (0.86–1.05) 1.12 (0.94–1.34) 0.94 (0.83–1.06)
P value 0.32 0.19 0.28
P value for homogeneity of slope coefficients between two subtypes = 0.04
Premenopausal African-American women
BMI at age 18 years, kg/m2
< 20.0 241 Referent 52 Referent 103 Referent
20.0–24.9 274 0.98 (0.72–1.33) 53 0.92 (0.56–1.50) 107 0.90 (0.61–1.35)
≥ 25.0 52 0.66 (0.40–1.13) 13 0.71 (0.31–1.65) 19 0.60 (0.29–1.24)
Per 5 kg/m2 increase 0.79 (0.62–1.00) 0.78 (0.54–1.15) 0.74 (0.54–1.03)
P value 0.05 0.21 0.07
P value for homogeneity of slope coefficients between two subtypes = 0.80
Recent BMI, kg/m2
< 25.0 271 Referent 58 Referent 114 Referent
25.0–29.9 160 0.92 (0.66–1.29) 29 0.79 (0.45–1.37) 64 0.93 (0.60–1.44)
≥ 30.0 136 1.02 (0.68–1.53) 31 1.09 (0.58– 2.05) 51 0.94 (0.55–1.59)
Per 5 kg/m2 increase 1.08 (0.92–1.25) 1.13 (0.90–1.43) 1.04 (0.85–1.28)
P value 0.35 0.30 0.69
P value for homogeneity of slope coefficients between two subtypes = 0.53
Abbreviations: ER estrogen receptor, PR progesterone receptor, HER2, human epidermal growth factor receptor-2, BMI body mass index
aORs obtained from multivariable polychotomous unconditional logistic regression models with mutual adjustment of BMI at age 18 years and recent BMI and
with adjustment for source study, study site, education, reference age, first-degree breast cancer family history, age at menarche, number of completed pregnancies,
lifetime recreational physical activity, alcohol intake, cigarette smoking status, and oral contraceptive use
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for premenopausal women and postmenopausal women
(≥ 27 vs. < 20 kg/m2, luminal A subtype hazard ratio
(HR) = 0.5, 95% CI = 0.4–0.8; luminal B subtype HR =
0.7, 95% CI = 0.3–1.4; HER2 HR = 0.6, 95% CI = 0.2–1.7;
basal subtype HR = 0.4, 95% CI = 0.1–1.1). Our results
also showed that BMI at age 18 years was inversely asso-
ciated with all tumor marker subtypes and additionally
suggested that the inverse association was stronger
among premenopausal women than among postmeno-
pausal women. The AMBER Consortium [5] presented
results separately for premenopausal and
postmenopausal women, reporting that, among premen-
opausal women, BMI at age 18 years was inversely asso-
ciated with risk of ER+ breast cancer but not with risk
of ER– breast cancer or TNBC (≥ 30 vs. 20–24.9 kg/m2,
ER+ OR = 0.65, 95% CI = 0.42–1.01; ER– OR = 1.00, 95%
CI = 0.63–1.58; TNBC OR = 1.08, 95% CI = 0.59–1.98).
However, among postmenopausal women in the AMBER
Consortium Study, it was inversely associated with the risk
of all subtypes of breast cancer (≥30 vs. 20–24.9 kg/m2,
ER+ OR = 0.62, 95% CI = 0.38–1.01; ER– OR = 0.78,
95% CI = 0.44–1.41; TNBC OR = 0.68, TNBC 95% CI =
Table 4 Adjusteda odds ratio (OR) and 95% confidence interval (CI) for joint effect of BMI at age 18 years and recent BMI in relation
to risk of breast cancer overall and luminal-like subtype in premenopausal women
BMI at age 18 years, kg/m2 Recent BMI, kg/m2 Controls All cases luminal-like (ER+ and/or PR+)
Number Number OR (95% CI) Number OR (95% CI)
Overall
< 20.0 < 25.0 472 952 Referent 540 Referent
< 20.0 25.0–29.9 96 184 0.93 (0.70–1.24) 92 0.79 (0.56–1.13)
< 20.0 ≥ 30.0 20 51 1.21 (0.69–2.13) 24 0.99 (0.50–1.96)
20.0–24.9 < 25.0 265 555 1.03 (0.85–1.25) 311 1.00 (0.79–1.26)
20.0–24.9 25.0–29.9 171 302 0.87 (0.69–1.10) 151 0.77 (0.58–1.02)
20.0–24.9 ≥ 30.0 107 210 0.86 (0.65–1.13) 115 0.84 (0.60–1.17)
≥ 25.0 < 25.0 21 38 0.89 (0.50–1.58) 17 0.65 (0.32–1.35)
≥ 25.0 25.0–29.9 32 47 0.75 (0.46–1.22) 26 0.79 (0.43–1.44)
≥ 25.0 ≥ 30.0 73 88 0.54 (0.38–0.78) 40 0.46 (0.29–0.73)
Restricted to studies in which cases’ ER/PR/HER2 status determined in a central laboratory
< 20.0 < 25.0 342 448 Referent 183 Referent
< 20.0 25.0–29.9 70 86 0.94 (0.66–1.35) 31 0.79 (0.49–1.29)
<20.0 ≥ 30.0 16 21 1.03 (0.52–2.05) 6 0.67 (0.25–1.83)
20.0–24.9 < 25.0 186 253 1.05 (0.83–1.34) 103 1.03 (0.75–1.42)
20.0–24.9 25.0–29.9 132 148 0.86 (0.65–1.15) 55 0.75 (0.51–1.11)
20.0–24.9 ≥ 30.0 81 89 0.78 (0.55–1.11) 37 0.79 (0.50–1.25)
≥ 25.0 < 25.0 15 23 1.09 (0.55–2.16) 8 0.83 (0.33–2.08)
≥ 25.0 25.0–29.9 27 23 0.68 (0.38–1.22) 11 0.76 (0.36–1.62)
≥ 25.0 ≥ 30.0 58 41 0.52 (0.33–0.81) 15 0.46 (0.25–0.86)
Restricted to invasive cases
< 20.0 < 25.0 472 849 Referent 485 Referent
< 20.0 25.0–29.9 96 169 0.94 (0.70–1.26) 86 0.83 (0.58–1.20)
< 20.0 ≥ 30.0 20 51 1.35 (0.77–2.38) 24 1.13 (0.56–2.28)
20.0–24.9 < 25.0 265 506 1.04 (0.85–1.27) 287 1.03 (0.81–1.32)
20.0–24.9 25.0–29.9 171 286 0.92 (0.72–1.17) 143 0.84 (0.62–1.13)
20.0–24.9 ≥ 30.0 107 201 0.89 (0.67–1.18) 114 0.94 (0.67–1.34)
≥ 25.0 < 25.0 21 33 0.87 (0.48–1.59) 14 0.58 (0.27–1.26)
≥ 25.0 25.0–29.9 32 44 0.80 (0.48–1.32) 25 0.89 (0.48–1.66)
≥ 25.0 ≥ 30.0 73 85 0.58 (0.40–0.84) 40 0.53 (0.33–0.85)
Abbreviations: ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor-2, BMI body mass index
aORs obtained from multivariable polychotomous unconditional logistic regression models with adjustment for source study, study site, race, education, reference
age, first-degree breast cancer family history, age at menarche, number of completed pregnancies, lifetime recreational physical activity, alcohol intake, cigarette
smoking status, and oral contraceptive use
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0.29–1.56). The Women’s Health Initiative Cohort
Study [26], which included only postmenopausal
women, demonstrated that BMI at age 18 years was as-
sociated with a 17% reduced risk of ER+ breast cancer,
but was not associated with TNBC (≥22.42 vs. <
19.33 kg/m2, ER+ OR = 0.83, 95% CI = 0.69–0.98;
TNBC OR = 0.94, 95% CI = 0.56–1.56). Based on our
pooled results and those of earlier studies, no conclu-
sion can be drawn as to whether the impact of BMI at
age 18 years varies by tumor subtype, but at least, all
studies support that BMI at age 18 years is inversely as-
sociated with risk of breast cancer.
Many previous epidemiologic studies showed that re-
cent BMI was inversely associated with premenopausal
women’s risk of breast cancer overall and hormone re-
ceptor positive breast cancer, but not with hormone re-
ceptor negative breast cancer or TNBC [3, 5]; however,
not many of these studies adjusted for BMI in late ado-
lescence in their analyses. Our models assessing effects
of recent BMI adjusting for BMI at age 18 years showed
only weak evidence of an inverse association between re-
cent BMI and luminal-like subtype; for example, we
found a 20% reduced risk of luminal-like subtype associ-
ated with recent obesity in premenopausal women. In
sensitivity analyses, we removed the variable, BMI at age
18 years, from our models (i.e., no adjustment for BMI at
age 18 years) and found that recent obesity was associated
with a 29% reduced risk of luminal-like subtype, but
was not associated with TNBC or HER2-enriched
subtype (≥ 30 vs. < 25 kg/m2, luminal-like OR = 0.71,
95% CI = 0.55–0.91; TNBC OR = 0.96, 95% CI = 0.67–
1.38; HER2-enriched OR =1.02, 95% CI = 0.60–1.73; per
5 kg/m2 increase, luminal-like OR = 0.90, 95% CI =
0.83–0.98; TNBC OR = 1.00, 95% CI = 0.89–1.12;
HER2-enriched OR = 1.02, 95% CI = 0.86–1.20, P for
homogeneity of slope coefficients per 5 kg/m2 increase
= 0.12, results not shown). Comparing the models with
adjustment to those without adjustment for BMI at age
18 years, we note that the magnitude of the protective
effect of recent obesity on premenopausal luminal-like
cancer was reduced from 29% to 20%. This could ex-
plain why we did not observe strong evidence of a
negative association between recent BMI and luminal-
like subtype of breast cancer in premenopausal women.
Nevertheless, we observed clear inverse associations of
all ER/PR/HER2-subtypes when assessing BMI at age
18 years after adjusting for recent BMI. Therefore, our
data provide evidence suggesting that BMI in late ado-
lescence plays a more important role than recent BMI
in premenopausal breast cancer development.
Although our data did not show strong evidence of an
inverse association between recent BMI and risk of pre-
menopausal breast cancer, our analyses of the joint effects
of BMI at age 18 years and recent BMI in premenopausal
women showed the greatest risk reductions for breast
cancer overall (46% reduction) and for luminal-like
subtype (54% reduction) when contrasting the highest
categories of the two variables with the lowest categor-
ies. These findings suggest that the reduced risk of pre-
menopausal breast cancer is maximized in women who
are consistently overweight or obese during the pre-
menopausal period. Moreover, our results showing a
greater reduction in risk for luminal-like subtype than
for breast cancer overall associated with recent BMI
and the lack of differences in risk reduction across
tumor subtypes associated with BMI at age 18 years
suggests that recent BMI is more important in deter-
mining risk of luminal-like subtype. Yet, results from
the AMBER Consortium showing a lack of any impact
of the joint effects of BMI at age 18 years and recent
BMI on premenopausal ER+ breast cancer risk differ
from our results [5]. Thus, further research is needed
to clarify such inconsistency.
It has been well-documented that estrogen and pro-
gesterone play important roles in breast tumorigenesis
[27–29]. A possible mechanism, the suppression of ovar-
ian function resulting in fewer ovulatory menstrual cycles
and lower levels of circulating ovarian hormones, that
may occur among overweight or obese women [30, 31],
could explain the observed inverse associations of BMI
at age 18 years and recent BMI with premenopausal
breast cancer.
As women pass through menopause, the beneficial ef-
fect of obesity on breast cancer risk is replaced by an ad-
verse effect, possibly due to the fact that an important
source of estrogen at this time comes from peripheral
adipose tissue, where androstenedione is aromatized and
converted to estrogen [32, 33]. It has been unclear how
long it takes for this transition to occur where BMI
changes from a protective factor to a risk factor for
breast cancer. Based on the estimates of Pike et al. [34],
it takes a decade for a BMI of 30 kg/m2 in a premeno-
pausal woman (at age 50 years, relative risk of 0.75) to
become a risk factor (relative risk of 1.20 at age 62 years).
MacInnis et al. [35] found that in the Melbourne Collab-
orative Cohort Study, BMI was not associated with risk
of breast cancer in women who were postmenopausal
for less than 15 years (per 5 kg/m2 increase, HR = 0.98,
95% CI = 0.82–1.18), but was associated with a 26% in-
creased risk (per 5 kg/m2 increase, HR = 1.26, 95% CI =
1.08–1.46) in women who were postmenopausal for
15 years or more, supporting the notion that prolonged
exposure to the proliferative effects of elevated circulat-
ing estrogens from adipose tissue is needed. In our
pooled data, the upper age limit of participants was
64 years, the average age at reference date for postmeno-
pausal women was 54 years, and only 9% of the
postmenopausal women were above age 62 years. Such
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under-representation of older women might, at least
partly, explain why we did not observe consistent positive
associations between recent BMI and breast cancer overall
or the luminal-like subtype in postmenopausal women.
Our data did show that recent obesity was associated
with a 1.5-fold increased risk of luminal-like subtype in
postmenopausal women who had never used MHT, but
not in those who had used MHT. This could be because
the conversion of androstenedione to estrogen in periph-
eral adipose tissue is negligible when exogenous hor-
mones artificially elevate the amount of circulating
estrogens to a comparable level in both lean and obese
women [36].
Our pooled analysis has several strengths, including its
size, especially the large number of case-patient partici-
pants with incident TNBC. Furthermore, the informa-
tion on body size measures and covariates used in this
analysis was collected by trained staff who administrated
standardized, in-person interviews using structured
questionnaires, which were nearly identical across the
three source studies. To our knowledge, we are the first
to report results on the associations of both early adult-
hood and recent BMI with ER/PR/HER2-defined sub-
types of breast cancer according to both menopausal
status and race.
Several limitations of the current study should be con-
sidered. First, our two BMI measures, BMI at age
18 years and recent BMI (representing BMI 5 years prior
to reference date), are based on self-reported measures
of weight and height. We cannot exclude the possibility
that some women may have misreported their weight or
height, which could result in the misclassification of
BMI. This classification could differ between case-
patient participants and control participants, but it is
unlikely to differ across ER/PR/HER2-defined case-
patient participants. Second, 29% of our case-patient
participants had missing data on both ER and PR or on
HER2. We compared the distribution of BMI at age
18 years and recent BMI between case-patient partici-
pants with known ER/PR/HER2-defined subtypes and
those in the undefined group. No statistically significant
differences in distribution were detected. Third, ER/PR/
HER2 status in two of our source studies [6, 7] was de-
termined in the same laboratory, using the same
methods, whereas, in the third source study [8], the in-
formation on ER/PR/HER2 status was collected from the
LACSP. Using the Women’s CARE Study, we conducted
a validation study, which showed that results for the as-
sociation between reproductive factors and risk of ER/
PR subtypes of breast cancer were similar regardless of
whether the source of ER/PR information was LACSP or
a single centralized laboratory [37]. At that time we were
unable to validate HER2 status because the Women’s
CARE Study cases had been diagnosed before HER2
data were available in SEER registry records. In addition,
when we repeated our analyses with only two of our
source studies with ER/PR/HER2 status from the cen-
tralized laboratory, the major results were similar (data
shown in Table 4). Fourth, the centralized laboratory
used IHC to assess HER2 protein overexpression in the
Women’s CARE Study and the Women’s BCIS Study,
and did not validate results using fluorescent in situ
hybridization (FISH). Based on previous validation re-
sults from the same pathology laboratory, 7.4% of breast
cancers with HER2 gene amplification in FISH analysis
were false negative by 10H8-IHC (scored as 0 or 1+) and
9.7% of breast cancers without HER2 gene amplification
in FISH analysis were false positive [18]. These misclassifi-
cations are unlikely to differ by BMI category, but could
cause bias towards the null for testing heterogeneity
across subtypes, such as TNBC versus HER2-enriched
subtype. Fifth, case-patient participants involved in this
analysis included those diagnosed with first primary histo-
logically confirmed invasive or in situ breast cancer. Be-
cause data are inconsistent regarding whether the BMI in
situ breast cancer association is similar to that of BMI
with invasive breast cancer [38, 39], we excluded the in
situ breast cancer cases and repeated our analyses; we
found that the major results based on invasive breast can-
cers only were similar to those based on both invasive
cases and in situ cases (data shown in Table 4).
Conclusions
Our findings indicate that high BMI near the end of ado-
lescence decreases risk of all ER/PR/HER2-defined sub-
types of premenopausal breast cancer and also suggest
that this benefit could be maximized among premeno-
pausal women who consistently have high BMI during
their premenopausal years.
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